StatLab Medical Products is set to become part of Leica Biosystems after the closure of an upcoming acquisition.

Leica Biosystems, an operating company of Danaher has entered into a definitive agreement to acquire privately held StatLab, a global developer and manufacturer of anatomical pathology products, from Linden Capital Partners and Audax Private Equity.

For more than 50 years, StatLab has been a trusted partner to anatomic pathology laboratories, providing a broad portfolio of high-quality products across the pre-analytical and analytical histology workflow. From specimen collection and tissue processing through slide preparation and staining, StatLab’s solutions help laboratories improve efficiency, standardization, and diagnostic quality. Built on a strong reputation for quality, innovation, and customer partnership, StatLab shares Leica Biosystems’ commitment to advancing cancer diagnostics and improving outcomes for patients worldwide.

The transaction is anticipated to close by the end of 2026 and is subject to customary conditions, including receipt of applicable regulatory clearances. Financial terms of the acquisition were not disclosed.

Visit Leica Biosystems for more information